The USPTO has been issuing patents at an increased rate over the years. While it took over 121 years to issue the first one million patents, it only took about 3 years to issue the last one million patents. Further, about four million patents have issued so far in the 21st Century.
William Geary is a Member in the firm and is based in our Boston office. He is an experienced patent and trademark attorney with a particular background in medical technology, polymers and advanced materials, and chemicals. Bill provides counsel on all phases of patent and trademark law, through development strategy, protection, and exploitation of patent and trademark rights. His clients include start-ups, large companies such as Johnson & Johnson, medical technology manufacturers, and research institutions such as Massachusetts General Hospital.
A variety of options are available to applicants to speed up patent application examination at the U.S. Patent and Trademark Office. Four of the more common programs are explored in depth below, and other options for speeding up examination are available in a previous post provided by Mintz Levin.
Track One Prioritized Examination
Track One examination allows an applicant to pay for prioritized examination and to receive a final disposition usually in less than one year (compared to two to four years for regular examination) from the time Track One status is granted. A final disposition may be a Notice of Allowance, a Final Rejection, or a Notice of Abandonment. The program on average boasts a first Office Action in approximately 4 months and final disposition in less than 8 months. Continue Reading Fast Track Examination in the U.S. Patent and Trademark Office
The University of Massachusetts’ Medical Device Development Center (M2D2) has launched the 5th Annual M2D2 $100K Challenge, an opportunity designed to showcase the innovative ideas and entrepreneurial spirit of seed and early-stage biotech and medical technology companies. Apply now!
The M2D2 $100K Challenge Program is sponsored in partnership with Mintz Levin, BD, Boston Scientific, MPR Product Development, Omni Components and R&Q (Regulatory & Quality Solutions). The M2D2 $100K Challenge will award up to $100,000 in service or grant awards provided by the program sponsors. Applicants from across the nation and beyond are invited to participate and past years have included entrepreneurs from Europe, Israel and throughout the eastern seaboard of the US. Continue Reading Med Tech and Biotech Entrepreneurs – $100k Challenge is OPEN for 5 More Days!
A recent U.S. District Court decision has clarified a potential danger when filing terminal disclaimers that contain overly-broad language. The U.S. District Court for the Northern District of Illinois in Hagenbuch v. Sonrai Systems interpreted the terminal disclaimer language “I hereby disclaim the terminal part of any patent granted on the above-identified application or any continuation of it” as applying to any continuation application claiming priority from the application in which this terminal disclaimer was filed. Hagenbuch v. Sonrai Systems, 2015 U.S. Dist. LEXIS 39083, *4 (N.D. Ill. Mar. 27, 2015) (emphasis added).
Continue Reading When Prior Terminal Disclaimers Continue to Punish Subsequent Applications: A Potential Danger in Filing an Overly-Broad Terminal Disclaimer